Diagnostic and prognostic potential of serum cell-free microRNA-214 in glioma.

Diagnostic and prognostic potential of serum cell-free microRNA-214 in glioma.

World Neurosurg. 2019 Feb 19;:

Authors: Wang J, Che F, Zhang J, Zhang M, Xiao S, Liu Y, Zhou L, Su Q, You C, Lu Y, Heng X

Abstract
OBJECTIVES: We aimed to expound feasibility of serum cell-free microRNA-214 (miR-214) as a noninvasive biomarker for glioma in this study.
PATIENTS AND METHODS: We detected expression of miR-214 in medium from 2 glioma cell lines to confirm whether it is secretory in screening phase. Then we verified cell-free miR-214 expression in serum samples from an independent set of 100 preoperative glioma patients, 30 matching postoperative patients and 100 healthy controls.
RESULTS: MiR-214 was secreted from glioma cell lines. Extracellular miR-214 levels were significantly overexpressed in preoperative serum from glioma patients, whereas its expression significantly decreased in matched postoperative serum. Upregulated cell-free miR-214 in serum was significantly associated with higher tumor grade, absence of isocitrate dehydrogenase (IDH), unmethylated methylguanine methyltransferase (MGMT) promoter. Extracellular miR-214 in serum could effectively distinguish glioma patients from healthy control (area under the curve; AUC = 0.885; 95% CI =0.833 to 0.926). Moreover, serum cell-free miR-214 was an independent prognostic indicator of overall survival (OS) for patients with glioma.
CONCLUSIONS: Serum cell-free miR-214 could serve as a promising noninvasive biomarker of glioma in tumor stratification, early diagnosis and prognostic evaluation.

PMID: 30794970 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader https://ift.tt/2tDKMWx